Opko Health, INC 10-Q quarterly reports

OPKO Health reports a 4% increase in total revenues for Q2 2026, driven by strong performance in intellectual property and product segments, while net loss narrows significantly.

OPKO Health reported a 17% decrease in total revenues for Q1 2026, primarily due to the divestiture of its oncology diagnostics business, while its pharmaceutical segment saw a 10% revenue increase.

OPKO Health reports Q3 2025 results, highlighting strategic asset sales, increased R&D investment, and a significant reduction in operating loss despite revenue declines in services and products.

OPKO Health, Inc. reported a significantly increased net loss for the second quarter and first half of 2025, primarily driven by substantial interest expenses from debt restructuring and the absence of prior year investment gains, despite operational improvements in its diagnostics segment following asset sales.

OPKO Health's Q1 2025 results show a net loss, with revenue impacted by divestitures and foreign exchange, while a pending sale of oncology assets to Labcorp is expected to close in the second half of 2025.

OPKO Health's Q3 2024 results show a net income of $24.9 million, driven by a gain from the sale of select BioReference assets, despite a decrease in overall revenue.

OPKO Health's second quarter 2024 results show a net loss, impacted by decreased revenue from intellectual property transfers, but the company also announced a share repurchase program and a debt refinancing.

OPKO Health's first quarter 2024 results show a net loss, impacted by decreased revenue from intellectual property transfers, while also announcing a significant agreement to sell select BioReference assets to Labcorp.